Methyl 3,4-dihydroxybenzoate is a novel and potent metabolite of antioxidant polyphenol.

Oltipraz (RP 35972; NSC 347901), a potential anticancer agent, is a potent Nrf2 activator and an inducer of Phase II detoxification enzymes such as glutathione-S-transferase (GST).

ML-385 is a novel, potent and selective NRF2 inhibitor (Nrf2: nuclear factor E2 related factor 2) with an IC50 of 1.9 µM.

Danshensu is a naturally occuring phenolic acid of caffeic acid derivatives isolated from Salvia miltiorrhiza, with wide cardiovascular benefit by activating Nrf2 signaling pathway.

Ezetimibe ketone is a phase-I metabolite of Ezetimibe (SCH58235; SCH-58235; Zetia, Ezetrol), which is a selective inhibitor of cholesterol absorption in the gut used to lower cholesterol levels.

Ezetimibe (also known as SCH-58235) is a potent and selective inhibitor of cholesterol absorption in the gut used to lower cholesterol levels.

Desfluoro-ezetimibe is the defluorinated impurity of ezetimibe (SCH-58235; SCH 58235; Zetia, Ezetrol), which is a Niemann-Pick C1-like1 (NPC1L1) inhibitor and an effective Nrf2 activator, and has been used to lower cholesterol levels.

Omaveloxolone (formerly known as RTA-408; Skyclarys; RTA408), an antioxidant inflammation modulator (AIM), is a 2nd generation member of the synthetic triterpenoid that can activate Nrf2 (a cytoprotective transcription factor) and inhibit NF-κB signaling.